Meloxicam Patent Expiration
Meloxicam was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Meloxicam Patents
Given below is the list of patents protecting Meloxicam, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xifyrm | US12263176 | Pharmaceutical liquid compositions of meloxicam | Jul 31, 2041 | Azurity |
| Qamzova | US12059423 | Meloxicam composition, pharmaceutical preparation and preparation method and use thereof | Jul 19, 2040 | Nanjing Delova |
| Anjeso | US10881663 | Method of treating pain in elderly patients with mild renal impairment | Mar 08, 2039 | Baudax |
| Anjeso | US11458145 | Methods of administering intravenous meloxicam in a bolus dose | Mar 08, 2039 | Baudax |
| Vivlodex | US9649318 | Formulation of meloxicam | Mar 31, 2035 | Iceutica Operations |
| Vivlodex | US9808468 | Formulation of meloxicam | Mar 31, 2035 | Iceutica Operations |
| Vivlodex | US9526734 | Formulation of meloxicam | Mar 31, 2033 | Iceutica Operations |
| Qmiiz Odt | US8545879 | Fast disintegrating compositions of meloxicam | Aug 31, 2030 | Tersera |
| Anjeso | US10709713 | Nanoparticulate meloxicam formulations | May 26, 2030 | Baudax |
| Anjeso | US11253478 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | May 26, 2030 | Baudax |
| Anjeso | US9974746 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | May 26, 2030 | Baudax |
| Anjeso | US10463673 | Nanoparticulate meloxicam formulations |
Feb 24, 2024
(Expired) | Baudax |
| Anjeso | US10471067 | Nanoparticulate meloxicam formulations |
Feb 24, 2024
(Expired) | Baudax |
| Anjeso | US8512727 | Nanoparticulate meloxicam formulations |
Dec 25, 2022
(Expired) | Baudax |
| Meloxicam |
US6184220 (Pediatric) | Oral suspension of pharmaceutical substance |
Sep 25, 2019
(Expired) | Avondale Pharms |
| Meloxicam | US6184220 | Oral suspension of pharmaceutical substance |
Mar 25, 2019
(Expired) | Avondale Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Meloxicam's patents.
Latest Legal Activities on Meloxicam's Patents
Given below is the list recent legal activities going on the following patents of Meloxicam.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 07 May, 2021 | US9808468 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Mar, 2021 | US8545879 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 16 Nov, 2020 | US9649318 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 16 Oct, 2020 | US9649318 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 29 Jun, 2020 | US9526734 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 22 May, 2020 | US9526734 |
| Patent Issue Date Used in PTA Calculation Critical
| 07 Nov, 2017 | US9808468 |
| Recordation of Patent Grant Mailed Critical
| 07 Nov, 2017 | US9808468 |
| Email Notification Critical
| 19 Oct, 2017 | US9808468 |
| Issue Notification Mailed Critical
| 18 Oct, 2017 | US9808468 |
Meloxicam's Family Patents
